Polymeric Nanoparticles for Inhibitory RNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery systems for inhibitory RNAs, such as siRNA, face challenges in achieving high concentrations and controlled, sustained release within cells and tissues, particularly for therapeutic applications, due to degradation by endogenous nucleases and immune responses, and existing nonviral systems like cationic liposomes are inefficient and toxic.
Innovation Solution
Polymeric nanoparticles encapsulating inhibitory RNAs, complexed with polycations like spermine and spermidine, are developed to enhance encapsulation efficiency and facilitate controlled, sustained release, allowing for deep tissue penetration and intracellular delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for gene delivery, then delivery efficiency is improved, but safety concerns arise due to potential immune responses and rapid clearance
Solution Approach 1:
The patent employs nonviral polymeric nanoparticles as temporary, disposable delivery vehicles that do not integrate into the host genome and do not trigger immune responses. These nanoparticles are designed to be cleared rapidly by the body after delivering their payload, eliminating the safety concerns associated with viral vectors and long-term immune activation.
Solution Approach 2:
The patent uses polymeric nanoparticles as intermediary carriers that facilitate RNA delivery without requiring viral components. These nanoparticles serve as a safe bridge between the administered RNA and the target cells, avoiding direct viral infection mechanisms while maintaining delivery efficiency through controlled release and cellular internalization.
2Adaptability or versatility
If cationic liposome complexes are used for RNA delivery, then nonviral delivery is achieved, but toxicity increases especially to mucosal epithelium
Solution Approach 1:
The patent modifies the delivery system by changing from cationic liposome complexes to polymeric nanoparticles with controlled surface charge and composition. This parameter change reduces membrane disruption and cytotoxicity while maintaining the ability to deliver RNA to target cells, especially through mucosal barriers.
Solution Approach 2:
The patent employs composite polymeric nanoparticles that combine biodegradable polymers with RNA-containing complexes. These composite structures provide both the protective encapsulation needed for RNA stability and the controlled release properties required for safe delivery, avoiding the toxicity associated with traditional cationic liposomes.
3Ease of operation
If inhibitory RNAs are administered naked, then simplicity of administration is maintained, but degradation by endogenous nucleases occurs
Solution Approach 1:
The patent introduces polymeric nanoparticles as protective intermediaries that encapsulate inhibitory RNAs during administration. These nanoparticles shield the RNA from endogenous nucleases in the extracellular environment while allowing the RNA to remain active once delivered to the target cell, thus maintaining both administration simplicity and RNA stability.
4Object-affected harmful factors
If existing nonviral delivery systems are used, then safety is improved, but controlled and sustained release is not achieved
Solution Approach 1:
The patent employs polymeric nanoparticles with dynamic release properties that respond to physiological conditions. The nanoparticle matrix is designed to degrade at controlled rates, providing sustained release of inhibitory RNAs over time while maintaining safety. The release kinetics can be tuned based on the specific therapeutic application and target tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymeric nanoparticles achieve high encapsulation efficiency and sustained release of inhibitory RNAs, enabling effective delivery and prolonged action, overcoming the limitations of existing systems by improving internalization and reducing toxicity.
Implementation Method 1
Inhibitory RNAs are complexed to polycations having at least two positive charges at physiologic pH
Implementation Method 2
The nanoparticles are designed to release encapsulated inhibitory RNAs in a controlled and sustained manner
Implementation Method 3
The nanoparticulate size of the polymeric particles provides for greater internalization of the particles by cells when compared with microparticulate polymeric particles
Data Source
AI summary
Polymeric nanoparticles encapsulating inhibitory ribonucleic acids (RNAs) and methods of their manufacture and use are provided. Advantageous properties of the nanoparticles include: 1) high encapsulation efficiency of inhibitory RNAs into the nano articles, 2) small size of the nanoparticles that increases cell internalization, and 3) sustained release of encapsulated inhibitory RNAs by the nanoparticles that allows for administration of an effective amount of inhibitory RNAs to cells or tissues over extended periods of time. Encapsulation efficiency of inhibitory RNAs into the nanoparticles is greatly increased by complexing the inhibitory RNAs to polycations prior to encapsulation. Methods of using the polymeric nanoparticles for treating or inhibiting diseases or disorders are provided.